Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year

Aims: To determine if macrolide resistant Streptococcus pneumoniae will be a major concern in areas that receive annual mass azithromycin distributions for trachoma. Methods: A cross sectional survey was conducted of nasopharyngeal S pneumoniae isolates for susceptibility to azithromycin 1 year after administering a single dose of azithromycin to treat trachoma in a village in Nepal. Results: S pneumoniae was isolated from 50 (86%) of 57 nasopharyngeal cultures and no resistance to azithromycin was detected. Conclusion: The authors were unable to demonstrate that mass azithromycin therapy for trachoma produced macrolide resistant S pneumoniae that persists until the next scheduled annual treatment.

[1]  J. Mathews,et al.  A targeted, single‐dose azithromycin strategy for trachoma , 2000, The Medical journal of Australia.

[2]  M. Jones,et al.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. , 1999, The Journal of antimicrobial chemotherapy.

[3]  J. Whitcher,et al.  Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area , 1999, The British journal of ophthalmology.

[4]  G. Rossolini,et al.  Patterns of Macrolide Resistance Determinants among Community-Acquired Streptococcus pneumoniae Isolates over a 5-Year Period of Decreased Macrolide Susceptibility Rates , 1999, Antimicrobial Agents and Chemotherapy.

[5]  T. Quinn,et al.  Azithromycin in control of trachoma , 1999, The Lancet.

[6]  S. Blower,et al.  Global elimination of trachoma: How frequently should we administer mass chemotherapy? , 1999, Nature Medicine.

[7]  M. Pfaller,et al.  Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[9]  J. Mathews,et al.  A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. Rubinstein,et al.  A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  K. Tabbara,et al.  Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. , 1996, Ophthalmology.

[12]  H. Whittle,et al.  Randomised controlled trial of single-dose azithromycin in treatment of trachoma , 1993, The Lancet.

[13]  S. West,et al.  A simple system for the assessment of trachoma and its complications. , 1987, Bulletin of the World Health Organization.